Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.

Patient Clinical Trials Panel
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 26th in Philadelphia, Pennsylvania. This panel is moderated by patient Jessica




